Benzinga | Feb 16, 2021 06:09AM EST

SVB Leerink Initiates Coverage On Amryt Pharma with Outperform Rating, Announces Price Target of $40

SVB Leerink analyst Ami Fadia initiates coverage on Amryt Pharma (NASDAQ:AMYT) with a Outperform rating and announces Price Target of $40.